高盛发表研报，引述药明康德管理层称，美国生物安全法案短期影响可控，7月没有明显的客户行为改变或终止订单，亦指在强劲订单带动下，会继续致力扩张多肽的产能，重申有信心可达成按年增长60%的全年指引。另外，管理层亦指，会继续透过回购A股来提升股东回报。Wuxi Apptec (02359) rose nearly 5%, as of the drafting, rose 4.66%, reported HKD 38.15, and the turnover was HKD 0.156 billion.
According to the Futubull Finance app, Wuxi Apptec (02359) rose nearly 5%, as of the drafting, rose 4.66%, reported HKD 38.15, and the turnover was HKD 0.156 billion.
In terms of news, Wuxi Apptec announced that the company plans to repurchase shares with its own funds, with a total amount of CNY 1 billion, to maintain the company's value and shareholders' equity. It is worth mentioning that this is the company's third CNY 1 billion-level A-share cancellation repurchase plan this year; Wuxi Apptec completed the first two repurchase plans on February 5th and May 22nd, repurchasing a total of CNY 2.9 billion of A-shares.
Goldman Sachs released a research report, quoting Wuxi Apptec's management as saying that the short-term impact of the U.S. Biosecurity Act is controllable, and there were no significant changes or terminations of orders in July. It also indicated that, driven by strong orders, the company will continue to expand the capacity of polypeptides, and reiterated its confidence in achieving a 60% year-on-year growth in the annual guidance. In addition, the management also stated that it will continue to enhance shareholder returns through A-share repurchases.
